8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) August 5, 2004


                         COMPETITIVE TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)



          Delaware                  1-8696                  36-2664428
          --------                  ------                  ----------
  (State of incorporation)     (Commission File)           (IRS Employer
                                    Number)              Identification No.)





1960 Bronson Road, Fairfield, Connecticut                                 06824
- --------------------------------------------------------------------------------
(Address of principal executive offices)                              (Zip Code)



Registrant's telephone number, including area code   (203) 255-6044
                                                     --------------


                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


                                   Page 1 of 3






Item 5.  Other Events and Regulation FD Disclosure.

         On August 5, 2004, the U.S. Court of Appeals for the Federal Circuit
denied LabCorp's petition for a rehearing or a rehearing en banc of a June 8,
2004 decision affirming the November 2002 decision in favor of the Company and
Metabolite Laboratories, Inc. in the LabCorp litigation.

         LabCorp's only remaining options now are either to accept the court's
decision or appeal the decision to the U.S. Supreme Court. We do not know what
course of action LabCorp will choose; however, ultimately we expect that the
original decision of the court will continue to be upheld in our favor.

         We have not received any cash nor have we recorded any revenue related
to the damages awarded in this lawsuit.

         For further information relating to this lawsuit, please refer to the
discussion in Note 9 under the heading "Contingencies" in Part I in our
Quarterly Report on Form 10-Q for the quarterly period ended April 30, 2004, and
under the caption "LabCorp", under "Legal Proceedings" in the Prospectus filed
with the Securities and Exchange Commission on May 6, 2004, under Rule 424(b)(3)
of the Securities Act of 1933.


Item 7.  Financial Statements and Exhibits.

(c) Exhibits.

         Exhibit No.     Description of Exhibit                          Page
         -----------     ----------------------                          ----
         99.1            Registrant's press release dated
                         August 5, 2004                                     3

                                    Signature
                                    ---------

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                   COMPETITIVE TECHNOLOGIES, INC.
                                   Registrant


Date:  August 6, 2004              /s/ John B. Nano
                                   --------------------------
                                   By: John B. Nano
                                       President and
                                       Chief Executive Officer

                                  Page 2 of 3

EX-99.1

                                                                    Exhibit 99.1

                 COMPETITIVE TECHNOLOGIES WINS HOMOCYSTEINE CASE

Fairfield, CT (August 5, 2004) - Competitive Technologies, Inc. (AMEX: CTT)
announced today that the US Court of Appeals for the Federal Circuit (CAFC)
ruled in favor of CTT and its clients against Laboratory Corporation of America
Holdings (LabCorp) (NYSE: LH). The CAFC has denied LabCorp's petition for a
rehearing or rehearing en banc win of the homocysteine assay patent infringement
case. On June 8, 2004 the CAFC had affirmed the August 2003 decision of the U.S.
District Court for the District of Colorado (CDC) in favor of CTT and its
clients against LabCorp.

Pursuant to the CDC order and judgment, CTT, the University of Colorado and
Columbia University had been awarded $2.1 million, and CTT's licensee,
Metabolite Laboratories, Inc. was awarded $4.5 million in damages and interest
in this five-year-old case. CTT expects to receive approximately $1 million of
the total award. LabCorp previously posted a $6.6 million bond to stay execution
of the monetary judgment by the CDC and to stay a permanent injunction from
performing homocysteine assays.

CTT and its clients have been receiving a 6% royalty on current homocysteine
assays conducted by LabCorp under CTT's patent rights as a result of a December
2002 CDC-directed agreement. In a separate case that has not been finalized, CTT
and its clients also filed for attorney fees and court costs. The assay patent
is derived from discoveries made by CTT's clients, Drs. Robert Allen and Sally
Stabler from the University of Colorado and the late Dr. John Lindenbaum from
Columbia University.

"CTT and its clients have successfully prevailed in multiple venues in this
important case," said John B. Nano, CTT's President and CEO. "We applaud CAFC's
decision to reaffirm the lower court's decision and will work with LabCorp for a
final licensing agreement."

Mr. Nano continued, "A part of CTT's strategy of turning technology solutions
into commercial dollars is the responsibility to protect the intellectual
property of its clients, its licensees and its shareholders. We will continue
our active program of collecting from patent infringers all previously withheld
royalties from all laboratories conducting homocysteine assays. We estimate that
there will be over 20 million homocysteine assays conducted in 2004."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology
transfer and licensing provider focused on the technology needs of its customers
and transforming those requirements into commercially viable solutions. CTT is a
global leader in identifying, developing and commercializing innovative
technologies in life, digital, nano, and physical sciences developed by
universities, companies and inventors. The global market for technology transfer
services is estimated at $150 billion annually. CTT maximizes the value of
intellectual assets for the benefit of its customers, clients and shareholders.
Visit CTT's website: www.competitivetech.net

Statements about our future expectations, including development and regulatory
plans, and all other statements in this document other than historical facts are
"forward-looking statements" within the meaning of applicable Federal Securities
Laws, and are not guarantees of future performance. These statements involve
risks and uncertainties inherent in our business, including those set forth
under the caption "Risk Factors" in our Prospectus filed with the SEC on May 6,
2004 under Rule 424 (b)(3) of the Securities Act of 1933, and other factors that
may be described in our other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement.

Direct inquiries to:  Johnnie D. Johnson, Strategic IR, Inc.
                      Tel. (212) 754-6565; Fax (212) 754-4333

                      E-mail: jdjohnson@strategic-ir.com
                      E-mail: ctt@competitivetech.net